What foreign investors look for before entering emerging biotech markets

Foreign direct investment in biotechnology does not follow incentives alone. It follows confidence. Despite the attention often given to tax benefits, subsidies and regulatory fast-tracks, experienced biotech investors prioritize a different set of criteria when assessing emerging markets.

The first question foreign investors ask is not what is being offered, but who is executing. Biotech investment is execution-heavy by nature. It requires navigating complex regulatory pathways, managing long development timelines, and coordinating across science, manufacturing and market access. Investors therefore look for local partners with demonstrated judgment, governance and operational capability.

Local execution capacity is the strongest signal of investability. Markets that rely solely on incentives without developing local expertise struggle to convert interest into long-term commitments.

Risk alignment matters. Foreign investors seek markets where local capital shares risk rather than outsourcing it. Co-investment structures signal conviction and reduce downside perception.

Regulatory clarity is decisive. Predictable timelines, consistent standards and transparent engagement matter more than preferential treatment.

Downstream infrastructure also matters. Manufacturing readiness, clinical trial networks and talent pipelines determine scalability and localization viability.

Finally, investors assess continuity. Biotech does not conform to short-term cycles. Policy stability and institutional memory attract patient capital.

FDI in biotech is earned through execution. Markets that demonstrate discipline, alignment and capability attract durable partnerships rather than transactional flows.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.